A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Primary Objective
To compare efficacy between Arm A (sonrotoclax plus zanubrutinib [SZ]) versus Arm B (venetoclax plus obinutuzumab [VO]), as measured by progression-free survival (PFS) determined by the independent review committee (IRC).
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
MANALI KAMDAR
Study ID
Protocol Number: 23-1756
More information available at ClinicalTrials.gov: NCT06073821
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers